Electrophysiology and Behavioral Assessment of the New Molecule SMe1EC2M3 as a Representative of the Future Class of Triple Reuptake Inhibitors
Open Access
- 20 November 2019
- Vol. 24 (23) , 4218
Abstract
SMe1EC2M3 is a pyridoindole derivative related to the neuroleptic drug carbidine. Based on the structural similarities of SMe1EC2M3 and known serotonin (5-HT), norepinephrine, and dopamine reuptake inhibitors, we hypothesized that this compound may also have triple reuptake inhibition efficacy and an antidepressant-like effect. PreADMET and Dragon software was used for in silico prediction of pharmacokinetics and pharmacodynamics of SMe1EC2M3. Forced swim test was used to evaluate its antidepressant-like effects. Extracellular in vivo electrophysiology was used to assess 5-HT, norepinephrine, and dopamine reuptake inhibition efficacy of SMe1EC2M3. PreADMET predicted reasonable intestinal absorption, plasma protein binding, and blood-brain permeability for SMe1EC2M3. Dragon forecasted its efficiency as an antidepressant. Using behavioral measurements, it was found that SMe1EC2M3 decreased immobility time and increase swimming time during the forced swim test (FST). Electrophysiological investigations showed that SMe1EC2M3 dose-dependently suppressed the excitability of 5-HT neurons of the dorsal raphe nucleus (DRN), norepinephrine neurons of the locus coeruleus (LC), and dopamine neurons of the ventral tegmental area (VTA). The SMe1EC2M3-induced suppression of 5-HT, norepinephrine, and dopamine neurons was reversed by the antagonists of serotonin-1A (5-HT1A; WAY100135), α-2 adrenergic (α2, yohimbine), and dopamine-2 receptors (D2, haloperidol), respectively. We conclude that SMe1EC2M3 is prospective triple 5-HT, norepinephrine, and dopamine reuptake inhibitor with antidepressant-like properties, however future studies should be performed to complete the pharmacological profiling of this compound.Keywords
Funding Information
- Vedecká Grantová Agentúra MŠVVaŠ SR a SAV (VEGA 2/0166/16, VEGA 2/0127/18 and VEGA-2/0046/18)
- Agentúra na Podporu Výskumu a Vývoja (APVV-15-0037 and APVV-15-0388)
- Slovenská Akadémia Vied (2013 Scholarship Award to E. Dremencov)
This publication has 48 references indexed in Scilit:
- Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive DisorderThe Canadian Journal of Psychiatry, 2016
- A Meta-Analysis of Oxidative Stress Markers in DepressionPLOS ONE, 2015
- Interaction Between Brain Histamine and Serotonin, Norepinephrine, and Dopamine Systems: In Vivo Microdialysis and Electrophysiology StudyJournal of Molecular Neuroscience, 2015
- Neurotransmitter Targeting in the Treatment of DepressionThe Journal of Clinical Psychiatry, 2013
- Factors influencing behavior in the forced swim testPhysiology & Behavior, 2013
- Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming testNeuroscience & Biobehavioral Reviews, 2005
- Dimensional complexity of the neuronal activity in a rat model of depressionNeuroReport, 2004
- Venlafaxine: Discrepancy between in vivo 5-HT and NE reuptake blockade and affinity for reuptake sitesSynapse, 1999
- The forced swimming test as a model for core and component behavioral effects of antidepressant drugsBehavioural Pharmacology, 1997
- Detection of serotonergic and noradrenergic antidepressants in the rat forced swimming test: the effects of water depthBehavioural Brain Research, 1995